Compare Heron Therapeutics Inc (HRTX) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Global X Defense Tech ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Global X Defense Tech ETF trades at $59.92 (market cap $6.38B). The key difference: Global X Defense Tech ETF is far larger — about 86.2× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 1,280,546). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Global X Defense Tech ETF for 44 Days on average.
| HRTX | SHLD | |
|---|---|---|
Market Cap | $74.04M | $6.38B |
Volume | 3,668,095 | 1,280,546 |
Sector | Health | Sector/Thematic |
52-Week High | $1.49 | $78.02 |
52-Week Low | $0.27 | $58.20 |
Typical Hold Time | 35 Days | 44 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SHLD (Global X Defense Tech ETF) trades at $58.74, down 2.2% on the day amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though oversold RSI readings at 10.99 (6-day) and 15.12 (12-day) suggest potential for near-term bounce. Recent institutional filings show increased buying interest from firms like Focus Financial Network (+55.4% stake) and Balefire LLC ($1.12M new position) in Q2 2026, indicating professional confidence in defense tech exposure.
The defense technology sector benefits from geopolitical tensions and rising global military budgets, with EU allies planning significant rearmament spending. However, the ETF's concentrated focus on emerging tech carries execution risks versus broader aerospace peers. Current technical weakness contrasts with fundamental tailwinds, creating a divergence that may resolve with either sector momentum recovery or continued ETF-specific pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
